Sangamo Therapeutics

Julie Person Joins Third Harmonic Bio as Chief Administrative Officer

Retrieved on: 
星期二, 六月 28, 2022
People, International University Audentes, Patient, McKesson Corporation, LinkedIn, Business, Therapy, Human resources, GLOBE, Company, Goal, KIT, Inflammation, Internal communications, Talent management, University, Allergy, Survival, Culture, Hives, Medicine, Leadership, Twitter, Pharmaceutical industry, Management, Sangamo Therapeutics

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation,today announced the appointment of Julie Person to chief administrative officer.

Key Points: 
  • CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation,today announced the appointment of Julie Person to chief administrative officer.
  • Behind the incredible science at Third Harmonic Bio are the talented and committed employees dedicated to advancing the next wave of medicine for allergy and inflammation, said Ms.
  • Person joins the Company from Neumora Therapeutics, where she served as Chief People Officer and oversaw Human Resources and Internal Communications.
  • Third Harmonic Bio is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation.

AGTC Announces Key Appointments to Leadership Team

Retrieved on: 
星期三, 六月 8, 2022
Eli Lilly, Company, Amgen, Daiichi Sankyo, Form 10-K, Applied Genetic Technologies Corporation, MBA, Central nervous system, Annual report, Degenerative disease, Forward-looking statement, CEO, Retina, GMP, Optogenetics, Nasdaq, Therapy, AAV, Ophthalmology, Risk, ACHM, Central nervous system disease, Patient, GLOBE, Neurotology, Technology, Achromatopsia, COVID-19, Sangamo Therapeutics, FACP, SEC, MD, Biogen, Medical Affairs Bureau, Engineering, Drug development, CNS, Pharmaceutical industry

Eduardo comes to AGTC from Sangamo Therapeutics, where he led good manufacturing practice (GMP) gene therapy manufacturing efforts, including new facility commissioning.

Key Points: 
  • Eduardo comes to AGTC from Sangamo Therapeutics, where he led good manufacturing practice (GMP) gene therapy manufacturing efforts, including new facility commissioning.
  • Prior to this, he held positions of increasing responsibility across many manufacturing programs at several companies, including Amgen, Eli Lilly and Zimmer.
  • We are excited to welcome Eduardo and David to AGTC as we advance our lead clinical programs in X-linked retinitis pigmentosa and achromatopsia, and expand our manufacturing capabilities, said Sue Washer, President, and CEO of AGTC.
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.

Third Harmonic Bio Appoints Edward R. Conner, M.D., as Chief Medical Officer

Retrieved on: 
星期一, 六月 6, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Science, Hoffmann-La Roche, Johns Hopkins School of Medicine, Company, CMO, Biology, Lead, Genentech, Survival, Hives, LinkedIn, Allergy, University of California, San Francisco, Disease, Inflammation, University, Duke University, KIT, Therapy, Patient, Asthma, Acquisition, Sangamo Therapeutics, Novartis, Twitter, Omalizumab, Medicine, Culture, Internal medicine, Pharmaceutical industry, International University Audentes

Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation, today announced the appointment of Edward R. Conner, M.D., to chief medical officer (CMO).

Key Points: 
  • Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation, today announced the appointment of Edward R. Conner, M.D., to chief medical officer (CMO).
  • Dr. Conner joins Third Harmonic Bio from Locanabio, where he served as chief medical officer.
  • Before Audentes, Dr. Conner served as chief medical officer of Sangamo Therapeutics.
  • Third Harmonic Bio is a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for allergy and inflammation.

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

Retrieved on: 
星期三, 六月 1, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Sangamo Therapeutics, Therapy, Patient, Technology, Investor, Nasdaq, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
    Date: Thursday, June 9 at 9:00 a.m. Eastern Time
    Date: Tuesday, July 12 at 2:45 p.m. Eastern Time
    Access links for presentations, panels and fireside chats will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations .
  • The presentations will also be available on the Sangamo Therapeutics website after the event.
  • Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline.
  • For more information about Sangamo, visit www.sangamo.com .

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

Retrieved on: 
星期四, 五月 5, 2022
Biotechnology, Pharmaceutical, Genetics, Health, COVID-19, Forward-looking statement, GAAP, STAAR, Q&A, Patient, Clinical trial, Program, Annual report, U.S. Securities and Exchange Commission, Investor, Cyprus Securities and Exchange Commission, ID, Technology, Research, Therapy, Video game, Pharmaceutical industry, Sangamo Therapeutics, Sanofi

Cash, cash equivalents and marketable securities as of March 31, 2022 were $400.3 million, compared to $464.7 million as of December 31, 2021.

Key Points: 
  • Cash, cash equivalents and marketable securities as of March 31, 2022 were $400.3 million, compared to $464.7 million as of December 31, 2021.
  • Sangamo will host a conference call today, May 5, 2022, at 4:30 p.m. Eastern Time, which will be open to the public.
  • This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
  • We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business.

Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
星期一, 五月 2, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Genetics, Forward-looking statement, Outline, Nasdaq, Factor X, CNS, Institutional review board, Cell, AAV, Patient, Gene, Annual report, Genetic code, U.S. Securities and Exchange Commission, 2021 Essex County Council election, Society, Traffic barrier, Technology, Research, Central nervous system, Therapy, Pharmaceutical industry, Vaccine, Powder metallurgy, Wood drying, Sangamo Therapeutics

Presentations will focus on the progression of Sangamos pre-clinical programs emerging from its genomic engineering platform.

Key Points: 
  • Presentations will focus on the progression of Sangamos pre-clinical programs emerging from its genomic engineering platform.
  • With protection from the blood-brain barrier, current gene delivery to the CNS continues to be an obstacle.
  • Sangamos AAV capsids are designed to overcome that barrier, providing broad CNS access while minimizing exposure to a patients pre-existing anti-AAV antibodies.
  • Sangamo will also present data from its CAR-Treg cell therapy platform, including outlining advancements in pre-clinical allogeneic Treg engineering.

Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast

Retrieved on: 
星期四, 四月 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Webcast, Nasdaq, Sangamo Therapeutics, Investor, Telephone, Therapy, ID, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2022 financial results after the market closes on Thursday May 5, 2022.
  • ET, which will be open to the public via telephone and webcast.
  • Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations .
  • Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients lives using gene therapy, cell therapy, and genome engineering.

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

Retrieved on: 
星期四, 四月 21, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Sangamo Therapeutics, Technology, Nasdaq, Patient, Therapy, Investor, Pharmaceutical industry, Lobster

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:
    Date: Wednesday, May 11th at 3:00 p.m. Eastern Time
    Date: Wednesday, May 18th at 3:05 p.m. Eastern Time
    Date: Tuesday, May 24th at 7:00 a.m. Eastern Time
    Access links for presentations, panels and fireside chats will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations .
  • The presentations will also be available on the Sangamo Therapeutics website after the event.
  • Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline.
  • For more information about Sangamo, visit www.sangamo.com .

Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

Retrieved on: 
星期二, 三月 29, 2022
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Risk, Therapy, Multiple sclerosis, Chronic kidney disease, Dialysis, ESRD, Trial of the century, United Kingdom, Kidney, Clinical trial, Chimeric antigen receptor T cell, Autoimmunity, HLA-A*02, University Medical Center Groningen, Survival, Research, Nephrotoxicity, Kidney transplantation, Holm–Bonferroni method, Cardiovascular disease, Medicine, CEO, Immune system, Safety, Technology, U.S. Securities and Exchange Commission, Hope, Inflammation, Nasdaq, COVID-19, Annual report, Patient, Cancer, Vaccine, Pharmaceutical industry, Sangamo Therapeutics, THE STEADFAST STUDY, SANGAMO THERAPEUTICS

I look forward to the dosing of more patients and seeing data from the study to understand the potential of TX200.

Key Points: 
  • I look forward to the dosing of more patients and seeing data from the study to understand the potential of TX200.
  • Kidney transplantation is the treatment of choice for patients with end-stage renal disease (ESRD) who must otherwise remain on long-term dialysis.
  • TX200 was designed with the potential to prevent kidney rejection by reducing local inflammation and promoting immunological tolerance to the graft.
  • This investigational cell therapy is being assessed in HLA-A2 negative patients receiving a mismatched HLA-A2 positive kidney from a living donor.

AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

Retrieved on: 
星期四, 三月 17, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Phrase, Twitter, Therapy, Program, Research, University, Glycogen storage disease type II, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Sangamo Therapeutics, Cystinosis, Nasdaq, FFPM, Skin, Risk, Compte rendu, COVID-19, AVRO, Safety, AES, Security (finance), Adult, Brain, Clinical trial, GlaxoSmithKline, CEO, Growth, AVR, MRCP, Industry, Hunter syndrome, Lists of diseases, VCN, Data collection, LinkedIn, Disease, Pharmaceutical industry, Medical device, Vaccine, Cryptocurrency, Hunting, Gaucher

(Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update.

Key Points: 
  • (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2021, and provided a business update.
  • Sustained engraftment has been observed in each of these patients, as evidenced by stable vector copy number (VCN) levels.
  • Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across these three patients.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.